Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 18/20 | 0.62 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29271887 | 0.92 | CD274 (0.63) | CD274PDCD1 | |
| SCHEMBL19788528 | 0.89 | CD274 (0.61) | CD274PDCD1 | |
| SCHEMBL23078795 | 0.87 | CD274 (0.58) | CD274PDCD1FFAR1 | |
| SCHEMBL19227778 | 0.83 | CD274 (0.72) | CD274 | |
| SCHEMBL16554860 | 0.82 | CD274 (0.71) | CD274PDCD1 | |
| SCHEMBL31106583 | 0.82 | F2 (0.65) | CD274PDCD1 | |
| SCHEMBL21549455 | 0.81 | CD274 (0.58) | CD274PDCD1 | |
| SCHEMBL1746611 | 0.80 | FFAR1 (0.79) | FFAR1FFAR4 | |
| SCHEMBL27844226 | 0.80 | CD274 (0.67) | CD274PDCD1 | |
| SCHEMBL19788562 | 0.80 | CD274 (0.70) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385478-A1 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | BIOGRAPH 55 INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-9872852-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HAVCR2, CD4 | CD274 121/4885PDCD1 258/4885FFAR1 3631/4885 |
| US-20200385478-A1 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | TP53, GZMB, CD47 | CD274 9/4885PDCD1 8/4885FFAR1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.